A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes

Diabetes Care

Volumn 23, Issue 11, 2000, Pages 1666-1671

  Raskin, Philip ^a   Klaff, Leslie ^b   Bergenstal, Richard ^c   Hallé, Jean Pierre ^e   Donley, David ^d   Mecca, Thomas ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Rainier Clinical Research Center   (United States)

^c INTERNATIONAL DIABETES CENTER   (United States)

^d IQVIA   (United States)

^e MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033766190     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.11.1666     Document Type: Article

References (18)

1. Insulin analogues
2. Improving insulin therapy: Achievements and challenges
3. Insulin-Arg2, a new retardation principle based on a natural proinsulin-derived processing intermediate
4. NovoSol Basal: Pharmacokinetics of a novel soluble long-acting insulin analogue
5. In vitro activity of biosynthetic human diarginylinsulin
6. Intravenous infusion of diarginylinsulin, an insulin analogue: Effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients
7. Controlling insulin bioavailability by crystal contact engineering
8. New insulin preparations with prolonged action profiles: A21-modified arginine insulins
9. HOE 901: A new insulin with prolonged action
10. Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE 901) in T1DM
11. Efficacy of HOE 901 following subcutaneous injection for four days in type I diabetic subjects
12. Efficacy and safety of HOE 901 in patients with type I DM: A four-week randomized, NPH insulin-controlled trial
13. Efficacy and safety of HOE 901 in patients with type 1 diabetes: A four-week randomised, NPH insulin-controlled trial
14. The effect of HOE 901 on glycemic control in Type 2 diabetes
15. Diabetic retinopathy
16. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
17. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
18. Insulin pharmacokinetics